Brief: Immix Biopharma Announces Heather Landau Joins Nexcella Scientific Advisory Board
18/08/2023 15:17
Aug 18 (Reuters) - Immix Biopharma Inc IMMX.O :
* IMMIX BIOPHARMA ANNOUNCES DR. HEATHER LANDAU, MEMORIAL
SLOAN
KETTERING CANCER CENTER AMYLOIDOSIS PROGRAM DIRECTOR, JOINS
NEXCELLA SCIENTIFIC ADVISORY BOARD
Source text for Eikon: ID:nGNX5Lnhrt
Further company coverage: IMMX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary